Abstract

Introduction: The majority of patients received chemotherapy alone (n=100, 71%).

Two recent studies have shown that CMI-guided therapy as measured by a PFS ratio ≥ 1.3. The median difference prior to CMI-guided therapy was 76 days longer in patients with clinical benefit, compared to being 44 days shorter in patients without benefit.

The median PFS in the MMP-guided line of treatment is 120 days compared to 89.5 days in the prior therapy line (p<0.001, HR = 0.54, 95% CI = 0.36–0.81).

After 1 year of FFS follow-up, 11 patients (8%) of patients treated according to MMP-guidance had a benefit compared to 3 patients (2%) treated according to the prior therapy line.

CMI-guided Treatments

• The majority of patients received chemotherapy alone (n=100, 71%).
• Twelve patients were treated alone, 5% in combination with chemotherapy (n=11, 8%) or hormone therapy (n=3, 4%).
• Finally, target and hormone therapy alone (4%) with a further 3 patients (2%) receiving hormone therapy in combination with chemotherapy.
• Three patients (2%) in the cohort received immunotherapy.

Conclusions

• These data confirm the feasibility and the benefit of using MPM to guide treatment selection and improve outcomes in heavily pretreated or refractory cancer patients in whom the next treatment choice is unclear.

Figure 3 - Kaplan-Meier showing FFS comparison in prior MMP-guided treatment line in 140 patients treated according to the MPP report.

Table 1 - Tumor types treated according to CMI report

Patient Selection

• In total, 202 patients were enrolled and profiled.
• Thirty-three patients (16%) were excluded from the analysis.
• Of the 169 remaining patients (82.2%) treated according to CMI-guidance, 3 patients (2%) were lost to follow up.

Tumor types treated according to CMI-guidance

Table 1 - Tumor types treated according to CMI report

Method

• Data from four independent studies where patients underwent molecular profiling as part of their clinical care were used in the post hoc analysis.

• Of the 202 cases studied, 191 were Caris Life Sciences (n=191) and 11 were profiled at Caris Molecular Laboratories (n=11).

• The majority of patients received chemotherapy alone (n=100, 71%).

• Twelve patients were treated alone, 5% in combination with chemotherapy (n=11, 8%) or hormone therapy (n=3, 4%).

• Finally, target and hormone therapy alone (4%) with a further 3 patients (2%) receiving hormone therapy in combination with chemotherapy.

• Three patients (2%) in the cohort received immunotherapy.

Results

• The median PFS in the MMP-guided line of treatment is 120 days compared to 89.5 days in the prior therapy line (p<0.001, HR = 0.54, 95% CI = 0.36–0.81).

• After 1 year of FFS follow-up, 11 patients (8%) of patients treated according to MMP-guidance had a benefit compared to 3 patients (2%) treated according to the prior therapy line.

• They were treated by 140 patients profiled using CMI (03/2010-12/2016) in Austria (n=40), United States (n=25), Lebanon (n=38) and Australia (n=37).

Data collected from 140 patients profiled using CMI over a 6-year period from 2010 to 2016.

Figure 1 - Study CONSORT diagram.

Figure 3 - waterfall plot showing the PFS difference between prior and MMP-guided therapy.

Figure 4 - Bar chart showing the distribution of CMI-guided treatments in 140 patients.